Ask AI
ProCE Banner Activity

Expert Perspectives on the Management of Patients With Relapsed/Refractory Follicular Lymphoma: Answers to Frequently Asked Questions

Clinical Thought

In this commentary, experts address questions about the role and utility of bispecific antibodies and CAR T-cell therapies in the management of follicular lymphoma and highlight factors guiding how they sequence these therapies for patients with relapsed/refractory disease.

Released: December 26, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with the Follicular Lymphoma Foundation

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Genentech, a member of the Roche Group, Incyte Corporation, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Genentech, a member of the Roche Group

Incyte Corporation

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Partners

Follicular Lymphoma Foundation

ProCE Banner

Target Audience

This activity is intended for hematologists, medical oncologists, and other healthcare professionals who care for patients with follicular lymphoma.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Develop communication strategies supporting patient engagement in care based on insights into the unmet needs of patients with relapsed/refractory follicular lymphoma

  • Evaluate the clinical rationale and emerging safety and efficacy evidence for novel treatments of patients with relapsed/refractory lymphoma

  • Plan chemotherapy-free treatment individualized to each patient with relapsed/refractory follicular lymphoma based on clinical evidence, expert recommendations, and patient/disease factors

  • Implement strategies supporting equitable access to novel therapies and clinical trials in underserved populations with relapsed/refractory follicular lymphoma

Disclosure

Primary Author

Peter Martin, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech, Genmab, PeproMene.

Gilles Salles, MD, PhD: consultant/advisor/speaker: AbbVie, BeOne, Bristol Myers Squibb, Ellipses, Foresight, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Lilly, Merck, ModeX, Novartis, Nurix, Pfizer, SERB, Treeline; researcher: AbbVie, Genentech, Genmab, Ipsen, Janssen.

Laurie H. Sehn, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Cargo, Chugai, Genmab, Incyte, Janssen, Kite/Gilead, Lilly, Merck, Roche/Genentech, Seagen; researcher (paid to institution): Roche/Genentech.